Low-molecular-weight heparins (LMWH) enoxaparin (Lovenox, J1650), dalteparin (Fragmin, J1645), fondaparinux (Arixtra, J1652) Oral anticoagulation (DOACs Direct Oral Anticoagulants): Rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa) reported via NDC on Medicare Part D claims Vitamin K antagonist: Warfarin (Coumadin) oral, Part D NDC
Women with previous unsuccessful diet attempts showed particularly strong responses, with 68% achieving clinically significant weight loss (greater than 5% of baseline body weight) compared to 12% in the placebo group
Prescribers who recommend it over FDA-approved alternatives must document in writing why those alternatives are contraindicated or insufficient for the individual patient
People deserve clear safety data, real efficacy trials, and honest language before a compound gets treated like legitimate medicine